End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
32.94 CNY | -0.09% | +3.52% | -20.55% |
Apr. 25 | Huadong Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 18 | Huadong Medicine's 2023 Profit Jumps 14% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.55% | 7.96B | B- | ||
+14.53% | 69.68B | C+ | ||
+7.11% | 8.21B | B | ||
-4.06% | 7.75B | C | ||
+2.26% | 4.64B | B- | ||
+17.12% | 4.32B | B+ | ||
-1.24% | 4.09B | B- | ||
-3.37% | 3.82B | B | ||
+21.42% | 3.62B | C+ | ||
+8.64% | 3.39B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000963 Stock
- Ratings Huadong Medicine Co., Ltd